GAD2 and Alzheimer disease: In both the CSF and temporal cortex of AD patients, total GABA levels are significantly reduced, accompanied by decreases in levels of glutamic acid decarboxylase (GAD) 65/67, GABAA receptors, and GABA transporters [57,71].